Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy

Patent metadata

Field	Value
Publication number	US-2016166693-A1
Application number	US-201615049198-A
Country	US
Kind code	A1
Filing date	Feb 22, 2016
Priority date	Jun 18, 2009
Publication date	Jun 16, 2016
Grant date	—

Abstract

Described herein are anti-cancer compounds composed of a macromolecule comprising (1) at least one anti-cancer agent directly or indirectly bonded to the macromolecule and (2) at least one high Z element directly or indirectly bonded to the macromolecule that is capable of producing Auger electrons upon exposure to X-ray energy. When the compounds are exposed to low energy X-ray (e.g., kilo electron volts KeV) Auger electrons are produced by the high Z elements present in the compound. Because lower energy is required when compared to typical radiotherapy, which uses therapeutic X-ray energy in the million electron volt range (MeV), the subject experiences lower collateral damage when compared to radiation therapy. Additionally, the presence of the anti-cancer agent provides a second mechanism for killing cancer cells. Methods for making and using the anti-cancer compounds are also described herein.

First claim

What is claimed is:

1 . A compound comprising a macromolecule comprising (1) at least one anti-cancer agent directly or indirectly bonded to the macromolecule and (2) at least one high Z element directly or indirectly bonded to the macromolecule that is capable of producing Auger electrons upon exposure to X-ray energy.

2 . The compound of claim 1 , wherein the compound comprises the formula I

wherein
X is a macromolecule;
L 1 and L 2 are a linker;
Y 1 comprises a high Z element group bonded to the linker L 1 ;
Y 2 comprises an anti-cancer agent covalently bonded to the linker L 2 ;
and m and n are, independently, an integer from 1 to 10.

3 . The compound of claim 1 , wherein the macromolecule comprises dextran, dextrin, hyaluronic acid, chitosan, polylactic/glycolic acid (PLGA), poly lactic acid (PLA), polyglutamic acid (PGA), polymaleic acid, polyaspartamides, polyethylene glycol (PEG N-(2-hydroxypropyl) methacrylamide (HPMA), polyvinylpyrrolidone, polyethyleneimine, polyamidoamine (linear), poly(amido amine) (PAMAM), diaminobutane (DAB), diaminoethane (DAE), and a dendrimer comprising polyamidoamine, polypropyleneimine, polyether, polylysine, or any combination thereof.

4 . The compound of claim 1 , wherein the macromolecule comprises a macromolecule derived from the polymerization of one or more monomers comprising N-(2-methylpropyl) methacrylamide, N-(2-methylethyl) methacrylamide, N-isopropyl methacrylamide, N,N-dimethacrylamide, N-vinylpyrrolidone, vinyl acetate, 2-methacryloxyethyl glycoside, acrylic acid, methacrylic acid, vinylphosphonic acid, styrenesulfonic acid, malic acid, 2-methacryloxyethyltrimethylammonium chloride, 2-methacrylamidopropyltrimethylammonium chloride, methacryloylcholine methyl sulfate, 2-methacryloxyethyltrimethylammonium bromide, 2-venyl-1-methylpyridinium bromide, 4-vinyl-1-methylpyridinium bromide, ethyleneimine, (N-acetyl)ethyleneimine, (N-hydroxyethyl)ethyleneimines, or allylamine.

5 . The compound of claim 3 , wherein the dendrimers comprises a range of 1 to 10 generations or half generations.

6 . The compound of claim 1 , wherein the macromolecule has a molecular weight of 10 kD to 200 kD.

7 . The compound of claim 1 , wherein the high Z element group comprises iodine, lutenium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, gold, thallium, lead, bismuth, radon, franceium, platinum or any combination thereof.

8 . The compound of claim 1 , wherein the high Z element group comprises platinum containing chemotherapeutic agent.

9 . The compound of claim 7 , wherein the platinum containing chemotherapeutic agent comprises cisplatin, carboplatin, oxiplatin, nedaplatin, lipoplatin, satraplatin, ZD0473, BBR3464, SPI-77, or any combination thereof.

10 . The compound of claim 1 , wherein the anti-cancer agent comprises a cell cycle specific compound.

11 . The compound of claim 1 , wherein at least one anti-cancer agent comprises abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, busulfan, calusterone, capecitabine, carmustine, celecoxib, cetuximab, cladribine, cyclophosphamide, cytarabine, carmustine, celecoxib, cetuximab, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, actinomycin, dateparin, darbepoetin, dasatinib, daunomycin, decitabine, denileukin, diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, eculizumab, epirubicin, epoetin, erlotinib, estramustine, etoposide, exemestane, fentanyl, filgrastim, floxuridine, 5-FU, fulvestrant, gefitinib, gemcitabine, gemtuzumab, ozogamicin, goserelin, histrelin, hydroxyurea, ibritumomab, tiuxetan, idarubicin, ifosfamide, imatinib, irinotecan, lapatinib, lenalidomide, letrozole, leucovorin, leuprolide, levamisole, lomustine, CCNU, meclorethamine, megestrol, melphalan, L-PAM, mercaptopurine, 6-MP, mesna, methotrexate, mitomycin C, mitotane, mitoxantrone, nadrolone, nelarabine, nofetumomab, oprelvekin, pegasparagase, pegfilgrastim, peginterferon alpha-2b, pemetrexed, pentostatin, pipobrman, plicamycin, mithramycin, porfimer, procarbazine, quinacrine, rasburicase, rituximab, sargramostim, sorafenib, streptozocin, sunitinib, talc, tamoxifen, temozolomide, teniposide, VM-26, testolactone, thalidomide, thioguanine, 6-thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, ATRA, Uracil Mustard, valrubicin, vinorelbine, vorinostat, zoledronate, zoledronic acid, or an analog thereof.

12 . The compound of claim 2 , wherein L 1 and L 2 comprises, independently, an oligopeptide sequence, an amino acid or amino acid sequence, polyethylene glycol, (PEG-diacrylate (PEGDA), PEG-dimethacrylate (PEGDM), PEG-diacrylamide (PEGDAA), or PEG-dimethacrylamide (PEGDMA).

13 . The compound of claim 12 , wherein the amino acid or amino acid sequence comprises SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, Gly-Ileu-Phe, Gly-Val-Phe, Gly-Gly-Phe, Gly-Ileu-Tyr, Gly-Gly, Gly-Phe, Gly-Leu-Phe, Gly-Phe-Phe, Gly-D-Phe-Phe, Gly-Phe-Tyr, Gly-□-Ala-Tyr, Gly-Leu, Gly-Phe-Gly, Phe, Gly, Ala, Ser, or any combination thereof.

14 . The compound of claim 12 , wherein the polyethylene glycol has a molecular weight from 62 D to 20 kD.

15 . The compound of claim 1 , wherein the compound further comprises a targeting group directly or indirectly bonded to the macromolecule.

16 . The compound of claim 1 , wherein the targeting group is covalently bonded to the linker.

17 . The compound of claim 15 , wherein the targeting group comprises a monoclonal antibody, a peptide, a somatostatin analog, a folic acid derivative, a lectin, a polyanionic polysaccharide, or any combination thereof.

18 . The compound in claim 15 , wherein the targeting group is indirectly bonded to the macromolecule by a linker.

19 . The compound of claim 2 , wherein X comprises a poly (amido amine) dendrimer, L 1 comprises one or more amino acids, and L 2 comprises polyethylene glycol.

20 . The compound of claim 19 , wherein Y 1 comprises a cisplatin group.

21 . The compound of claim 20 , wherein Y 2 comprises a camptothecin or an analog thereof.

22 . A method of reducing or preventing tumor cell proliferation comprising (1) contacting the tumor cells with an effective amount of a compound of claim 1 and (2) exposing the cells to X-ray energy at a sufficient level to produce an Auger electron.

23 . The method of claim 22 , wherein the X-ray energy is sufficient to remove a K-shell electron from the high Z element.

24 . The method of claim 22 , wherein the X-ray energy is sufficient to remove a L-shell electron from the high Z element.

25 . The method of claim 22 , wherein the tumor comprises a breast tumor, a testicular tumor, an ovarian tumor, a lymphoma, leukemia, a solid tissue carcinoma, a squamous cell carcinoma, an adenocarcinoma, a sarcoma, a glioma, a blastoma, a neuroblastoma, a plasmacytoma, a histiocytoma, an adenoma, a hypoxic tumor, a myeloma, a metastatic cancer, and AIDS-related lymphoma or sarcoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cance

Assignees

• Univ Utah Res Found

Inventors

• Ghandehari Hamid
• Ray Abhijit

Classifications

• A61K41/00 Primary

  Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61N5/10

  X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence) · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title